[Approach to examining hypercalcemia in the clinical laboratory]

Hypercalcemia is a common clinical finding requiring accurate diagnosis to distinguish primary hyperparathyroidism from other causes. Prior research has shown that standard biochemical tests often fail to differentiate these conditions reliably. This gap motivated the development of a more precise diagnostic approach. Established knowledge includes the role of serum calcium and parathyroid hormone levels in diagnosing hyperparathyroidism. However, no prior work had resolved how to adjust for confounding factors like albumin levels. This paper's contribution is a novel two-step discriminant analysis method to improve diagnostic accuracy. The study also addresses the underappreciated impact of low albumin in masking true calcium levels. This work builds on existing literature but introduces a new screening protocol. The need for better diagnostic tools remains unmet in clinical practice.

The aim of this study was to develop and validate a screening method for primary hyperparathyroidism among hypercalcemic patients. The specific problem addressed is the difficulty in distinguishing PHPT from non-parathyroid causes of hypercalcemia. The motivation stems from the high misdiagnosis rate in routine clinical settings. The study sought to create a reliable diagnostic algorithm using biochemical parameters. It also aimed to address the issue of albumin-adjusted calcium interpretation. The researchers proposed that combining discriminant functions would enhance diagnostic accuracy. They further investigated the need for calcium adjustment in patients with low albumin. This approach was designed to improve clinical decision-making in hypercalcemia cases.

The study used discriminant analysis with stepwise variable selection to derive diagnostic functions. Seven PHPT patients and fifty-one NPHC patients were analyzed in a retrospective phase. Three biochemical parameters were selected for the first discriminant function (F1). A second function (F2) was derived from three additional parameters in F1-positive patients. The combined functions achieved 100% sensitivity and 98% specificity. Prospective validation was conducted on fifty-six new hypercalcemic cases. The second part of the study focused on calcium adjustment. A formula was developed using 6,821 specimens with calcium and albumin measurements. The adjustment formula was tested prospectively on fifty patients with hypercalcemia.

The combined discriminant functions (F1 and F2) correctly identified all PHPT cases in the retrospective cohort. In the prospective validation, the method maintained 100% sensitivity and 98% specificity. The study found a high malignancy rate (54%) among hypercalcemic patients. This finding suggested the need for calcium adjustment in patients with low albumin. The adjustment formula was derived from a linear relationship between calcium and albumin. Using this formula, 6% of specimens within the reference interval had elevated calcium after adjustment. In specimens below the lower limit, 88% showed elevated calcium after adjustment. Prospective testing confirmed that 62% of patients had abnormal calcium levels after adjustment.

The authors proposed that their two-step discriminant analysis method is effective for diagnosing PHPT in hypercalcemic patients. They emphasized the importance of combining multiple biochemical parameters for improved accuracy. The study confirmed that the method maintains high sensitivity and specificity in prospective validation. The researchers also highlighted the need for calcium adjustment in patients with low albumin. They proposed that this adjustment is necessary to detect masked hypercalcemia in malignancy cases. The adjustment formula was shown to be clinically useful in identifying abnormal calcium levels. The authors suggested that this approach should be integrated into routine diagnostic protocols. These findings provide a practical solution to a known diagnostic challenge.